Zika virus infection future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| (9 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Zika virus}} | {{Zika virus}} | ||
{{CMG}} {{AE}} {{YD}} | {{CMG}} {{AE}} {{YD}}; {{NRM}} | ||
==Overview== | ==Overview== | ||
There is currently no vaccine in advanced development to prevent Zika virus infection. | There is currently no vaccine in advanced development to prevent Zika virus infection. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
*There is currently no vaccine in advanced development to prevent Zika virus infection. | *There is currently no vaccine in advanced development to prevent Zika virus infection. | ||
*It is unknown if vaccines against other flaviviruses are effective against Zika virus. | *It is unknown if vaccines against other flaviviruses are effective against Zika virus. The efficacy and safety of vaccines currently under development against [[Chikungunya virus]] are being studied in pre-clinical experiments for Zika virus.[http://www.9news.com.au/national/2016/02/01/18/47/adelaide-researchers-vaccine-could-be-adapted-to-tackle-zika-virus] | ||
*In February 2016, Sanofi, Pfizer, Johnson and Johnson, Merck,and Takeda announced the launching of projects to develop vaccines against Zika virus using either new technologies or existing vaccines.[http://www.reuters.com/article/us-sanofi-zika-idUSKCN0VB0E3][http://in.reuters.com/article/us-health-zika-big-pharma-idINKCN0VC1EB?feedType=RSS&feedName=health&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+reuters%2FINhealth+%28News+%2F+IN+%2F+Health%29] | |||
*Recent animal studies have shown that human monoclonal antibodies against Zika virus envelope (E) protein, isolated from individuals with prior Zika virus infection, reduce tissue pathology, maternal-fetal transmission, and mortality when injected in mice.<ref name="pmid27819683">{{cite journal| author=Sapparapu G, Fernandez E, Kose N, Cao B, Fox JM, Bombardi RG et al.| title=Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. | journal=Nature | year= 2016 | volume= | issue= | pages= | pmid=27819683 | doi=10.1038/nature20564 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27819683 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Dermatology]] | |||
[[Category:Pulmonology]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Neurology]] | |||
Latest revision as of 00:46, 30 July 2020
|
Zika virus infection Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zika virus infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Zika virus infection future or investigational therapies |
|
FDA on Zika virus infection future or investigational therapies |
|
CDC on Zika virus infection future or investigational therapies |
|
Zika virus infection future or investigational therapies in the news |
|
Blogs on Zika virus infection future or investigational therapies |
|
Risk calculators and risk factors for Zika virus infection future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Nate Michalak, B.A.
Overview
There is currently no vaccine in advanced development to prevent Zika virus infection.
Future or Investigational Therapies
- There is currently no vaccine in advanced development to prevent Zika virus infection.
- It is unknown if vaccines against other flaviviruses are effective against Zika virus. The efficacy and safety of vaccines currently under development against Chikungunya virus are being studied in pre-clinical experiments for Zika virus.[2]
- In February 2016, Sanofi, Pfizer, Johnson and Johnson, Merck,and Takeda announced the launching of projects to develop vaccines against Zika virus using either new technologies or existing vaccines.[3][4]
- Recent animal studies have shown that human monoclonal antibodies against Zika virus envelope (E) protein, isolated from individuals with prior Zika virus infection, reduce tissue pathology, maternal-fetal transmission, and mortality when injected in mice.[1]
References
- ↑ Sapparapu G, Fernandez E, Kose N, Cao B, Fox JM, Bombardi RG; et al. (2016). "Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice". Nature. doi:10.1038/nature20564. PMID 27819683.